Project Description

In The Media…

Hospital & Healthcare Management

December 16, 2021

The risk of infection with the transperineal approach to prostate biopsy is nearly 0%. As a result, adoption of the PrecisionPoint™ Transperineal Access System has the potential to help ease the economic burden associated with treating infections caused by the transrectal approach. Dr. Matthew Allaway, founder and CEO of Perineologic, explains in this HHM Global (Hospital & Healthcare Management) article.

“By significantly reducing the risk of infection, a transperineal biopsy may decrease costs associated with treating infections, especially those resulting in hospitalizations and sepsis, which can be substantial for both healthcare providers and patients.”

Dr. Matthew J. Allaway
Founder & President, Perineologic

Share This Page...

Share This Page...

RETURN TO THE “MEDIA CENTER”

Have a Question? Contact Us!

Thank you for your interest in Perineologic!

    Other Ways to Contact Us

    • (240) 727-7662

    • john@perineologic.com

    • Perineologic
      183 N. Centre Street
      Cumberland, MD 21502
      United States

    ML-001-03revB